产品封面图

CRL-2279 MS1 小鼠胰岛内皮细胞

收藏
  • 询价
  • ATCC
  • CRL-2279 MS1
  • 2025年12月22日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 供应商

      上海复祥

    • 器官来源

      小鼠

    • 库存

      大量

    CRL-2279 MS1 小鼠胰岛内皮细胞,原代细胞|细胞系|细胞株|菌种;细胞库管理规范,提供的细胞株背景清楚,提供参考文献和最优培养条件!

    CRL-2279 MS1 小鼠胰岛内皮细胞 的详细介绍

    CRL-2279 MS1 小鼠胰岛内皮细胞
    ATCC® Number: CRL-2279™
    Designations: MS1 (MILE SVEN 1)
    Depositors: JL Arbiser
    Biosafety Level: 2 [CELLS CONTAIN PAPOVAVIRUS ]
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: adherent
    Organism: Mus musculus (mouse)
    Morphology: endothelial


    Source: Organ: pancreas
    Strain: C57BL/6
    Tissue: islet of Langerhans; endothelium
    Cell Type: SV40 transformed
    Cellular Products: tissue inhibitor of bioreactive matrix metalloproteinase (high levels)
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

    Receptors: vascular endothelial growth factor (VEGF), expressed
    Comments: MS1 is a pancreatic islet endothelial cell line established in 1994.
    Primary islet endothelial cells were transduced with a temperature sensitive SV40 large T antigen (tsA-58-3) constructed and screened for resistance to G418.
    Resistant colonies were isolated in cloning rings and screened for uptake of diI-Ac-LDL.
    The line retains many properties of endothelial cells including uptake of acetylated LDL and expression of both Factor VIII related antigen and VEGF receptor.
    The cells are useful for the study of signal transduction of angigenic factors.
    It is the only line known that can give rise to benign hemangiomas.
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 5%.
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Temperature: 37.0°C
    Subculturing: Protocol:
    Remove and discard culture medium.
    Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
    Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
    Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
    Add appropriate aliquots of the cell suspension to new culture vessels.
    Incubate cultures at 37°C.

    Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
    Medium Renewal: 2 to 3 times per week
    Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
    Storage temperature: liquid nitrogen vapor phase
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
    recommended serum:ATCC 30-2020
    References: 22603: Arbiser JL, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94: 861-866, 1997. PubMed: 9023347
    51452: Arbiser JL, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am. J. Pathol. 156: 1469-1476, 2000. PubMed: 10751370


    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    • 实验室常用细胞株

      内皮细胞、贴壁 F-12K, 10% FBS 和 肝素盐 100 ug/ml HX [HT1080 xeno] CRL-12011 人 纤维肉瘤 上皮细胞、贴壁 DMEM, 10% FBS细胞株名称 ATCC 编号 细胞来源 细胞种类 生长状态 使用培养基 I-10 CCL-83 小鼠 睾丸癌 上皮细胞、贴壁 F-10, 15% HS和2.5% FBS IEC-6 CRL-1592 大鼠 正常小肠 上皮样、贴壁 DMEM, 5% FBS,胰岛素0.1μg/ml IM-9 CCL-159

    • 体液抗肿瘤免疫效应机制

      体内,在溶酶体酶作用下被溶解和破坏。血清中被激活的补体成分C3b和C5a通过和吞噬细胞表面CRl的结合,也可提高吞噬细胞的活性,增强对肿瘤细胞的作用。     (2)抗体抑制肿瘤细胞增殖和转移作用:某些肿瘤抗原是与肿瘤细胞的恶性转化、增殖和转移密切相关的蛋白质,抗体与肿瘤抗原结合后,发挥阻遏作用。如某些肿瘤细胞中HER-2/lieu基因激活异常表达p185,应用抗p185抗体与膜表面p185结合,可阻断其生物学活性,抑制肿瘤细胞的增殖。抗体还可封闭某些肿瘤细胞转铁蛋白受体。抑制

    • 免疫细胞的各种受体

      的Fc段可以与相应的Fc受体(FcR)结合,传递各种信号,参与多种免疫细胞介导的效应作用或参与免疫调节。其中FcγRⅡ、FcεRⅢ和FcεRⅠ分别参与B细胞的负向调节、ADCC杀伤和超敏反应。       5.其他免疫细胞受体或免疫应答相关受体     (1)补体受体:包括CRl、CR2、CR3、CR4、CR5等,分别表达于红细胞、B细胞、单核/巨噬细胞、嗜酸粒细胞和中性粒细胞,与相应补体活性片段结合后,介导各种生物学效应。       (2)归巢受体:使淋巴细胞在外周淋巴器官和组织

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥800
    上海信裕生物科技有限公司
    2025年07月12日询价
    ¥800
    上海再康生物科技有限公司
    2025年11月20日询价
    ¥600
    上海盖宁生物科技有限公司
    2026年01月01日询价
    ¥800
    上海康朗生物科技有限公司
    2025年07月13日询价
    CRL-2279 MS1 小鼠胰岛内皮细胞
    询价